
Latigo Biotherapeutics
LTGOPro trackingLatigo Biotherapeutics, Inc. · Nasdaq · Non-opioid pain therapeutics · Research source · 424B4 · Research as of 2026/08/07 · Latest filing · 10-Q · 2026-11-05 SEC ↗ · SEC checked 2026-11-21
Saved research available · 424B4
Latigo Biotherapeutics is offering 19.2 million shares of common stock at $18.00 per share under ticker LTGO, with estimated net proceeds of approximately $315.7 million.
Updates and this research have separate source dates; newer facts do not silently replace earlier conclusions.
Newly listed — review valuation, deal quality and post-IPO supply before acting
A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition. The IPO priced at $18.00 and raised $345.60M.
Full source-backed summary
A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition. The IPO priced at $18.00 and raised $345.60M. The latest market-value reference is $1.41B; reported revenue is Pre-revenue and net result is $(111.18M). The offer figures are reconciled to the final prospectus.
- Business and development direction
A clinical-stage developer of non-opioid pain medicines built around NaV1.8 inhibition.
Current business Non-opioid pain therapeutics100%
Future development Future direction not yet disclosed
Key risks
Risk 1
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
Risk 2
The latest reported period remains loss-making.
Risk 3
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | This saved report has no compatible source inputs for this calculation. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio · calculated | Shares |
|---|---|---|---|---|
| 1 | Goldman Sachs & Co. LLC | 39.00% | 7,488,000 shares | |
| 2 | Jefferies LLC | 28.00% | 5,376,000 shares | |
| 3 | Leerink Partners LLC | 21.00% | 4,032,000 shares | |
| 4 | Guggenheim Securities, LLC | 12.00% | 2,304,000 shares |
Ratio = institution commitment ÷ complete source-table total (19,200,000 shares) × 100.
Underwriting terms
| Measure | Reported value | Unit |
|---|---|---|
| Underwriting discount per share | $1.26 | $ / share |
| Total underwriting discount | $24,192,000 | $ |
Source and calculation
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 4; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗IPO CAPITAL QUALITY
Basis and evidence
No estimate is substituted for missing offer terms.
Capital quality is not yet quantifiable from the filed terms. IPO177 will calculate it when primary/secondary shares, fees and net proceeds are all disclosed.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 19,200,000 | Shares |
| Offering price | $18 | $ / share |
| Gross offering amount | $345,600,000 | $ |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 41 row 2; source 99779:104922; SHA256 dc31d5aadf19fcd5734c04b63c9d99159d8925aa22906fc8c05a1c96a2db66b7 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
SEC table 1 row 3; source 3604:6153; SHA256 e4a54bc92e921aea182ba8e49ae944e3d84c851f588503dc93806ade197fdd76 ↗Dilution and valuation
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Base post-offer valuation | ≈ 63.238M | ≈ $1.1383B | |
| Post-offer shares — base/no option | 63,238,030 | — | |
| Post-offer shares — full option | 66,118,030 | — | |
| Capitalization shares — actual | 925,193 | — | |
| Capitalization shares — pro forma | 44,038,030 | — | |
| Capitalization shares — pro forma as adjusted | 63,238,030 | — | |
| Shares offered | 19,200,000 | — | |
| Offering price | — | $18 | |
| Gross offering amount | — | $345,600,000 |
Basis and evidence ↗
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: actual; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Capitalization share count; source stage: pro forma as adjusted; Common stock, $0.0001 par value; 342,000,000 shares authorized, 925,193 shares issued and outstanding, actual; 999,999,999 shares authorized, 44,038,030 shares issued and outstanding, pro forma; 999,999,999 shares authorized, 63,238,030 shares issued and outstanding, pro forma as adjusted; this stage is not reclassified as an IPO equity-value denominator
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Base prospectus offering; cover per-share and total columns
Base prospectus offering; cover per-share and total columns Figures retain their stated source scenario and conditions.
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Offering price: $18
Exact input · Post-offer shares — base/no option: 63,238,030
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — full option: 66,118,030
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
completion-of-this-offering
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Base prospectus offering; cover per-share and total columns
Prospectus share summary; Common stock to be outstanding immediately after this offering; 63,238,030 shares (or 66,118,030 shares if the underwriters exercise their option to purchase additional shares in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Exact input · Post-offer shares — base/no option: 63,238,030
Exact input · Offering price: $18
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Offering completion · $18 × ≈ 63.238M shares · Final
Source and calculation ↗
Reported point prices retain their security, class, currency and per-security unit; range endpoints remain separate.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Equity value is the exact product of the selected compatible per-share price and whole-issuer post-offer count.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
The exact selected base supports transparent hypothetical price/share changes; it is not a forecast or tradable float.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
These saved displays are not verified valuation inputs. Their stage, precision and assumptions have not been established by the current source.
IPO price · 19.200M · $345.60M · $18.00
Latest shares outstanding · 63.24M · $1.41B · Market snapshot
Revenue reference · — · Pre-revenue · —
Net-result reference · — · $(111.18M) · Loss-making
$18 × 63,238,030 = $1,138,284,540 [summary-table-41-base-6-price, summary-table-41-base-6-post]
Exact calculation · Derived whole-issuer equity value: $1,138,284,540
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Comparable ownership figures across stages are unavailable in this report. See Control for holdings on their disclosed basis. Open filing ↗ |
Latest available filing
- Economic
- ~30.4%*
- As of
- 2026/08/07
Relationship filters
Select for details · Latigo Biotherapeutics
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| our executive officers, directors and stockholders whoOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: owned; primary source clause; full source conditions retained; source scope: of our outstanding common stock before this offering and their respective affiliates will,; not an additive ownership partition |
| Entities affiliated with Westlake BioPartnersOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with Foresite CapitalOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with 5AM VenturesOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Entities affiliated with Westlake BioPartnersOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Entities affiliated with Blue Owl HealthcareOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with Westlake BioPartnersOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with 5AM VenturesOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition |
| Entities affiliated with Foresite CapitalOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with Foresite CapitalOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with Blue Owl HealthcareOwnership as disclosed | — | >5%Beneficial | — | Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition |
| Entities affiliated with Westlake BioPartnersBeneficial shares | 13,199,669 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Entities affiliated with Westlake BioPartnersBeneficial shares | 13,199,669 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Entities affiliated with Foresite CapitalBeneficial shares | 9,041,328 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Entities affiliated with Foresite CapitalBeneficial shares | 9,041,328 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Entities affiliated with 5AM VenturesBeneficial shares | 7,325,962 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Entities affiliated with 5AM VenturesBeneficial shares | 7,325,962 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Entities affiliated with Blue Owl HealthcareBeneficial shares | 3,146,780 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Entities affiliated with Blue Owl HealthcareBeneficial shares | 3,146,780 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Deep Track Biotechnology Master Fund, Ltd.Beneficial shares | 2,496,656 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Deep Track Biotechnology Master Fund, Ltd.Beneficial shares | 2,496,656 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Nima FarzanBeneficial shares | 2,902,419 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Nima FarzanBeneficial shares | 2,902,419 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Entities affiliated with Westlake BioPartnersBeneficial ownership | — | 29.9%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Entities affiliated with Westlake BioPartnersBeneficial ownership | — | 20.9%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Entities affiliated with Foresite CapitalBeneficial ownership | — | 20.5%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Entities affiliated with Foresite CapitalBeneficial ownership | — | 14.3%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Entities affiliated with 5AM VenturesBeneficial ownership | — | 16.6%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Entities affiliated with 5AM VenturesBeneficial ownership | — | 11.6%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Entities affiliated with Blue Owl HealthcareBeneficial ownership | — | 7.1%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Entities affiliated with Blue Owl HealthcareBeneficial ownership | — | 5%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Deep Track Biotechnology Master Fund, Ltd.Beneficial ownership | — | 5.7%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Deep Track Biotechnology Master Fund, Ltd.Beneficial ownership | — | 3.9%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Nima FarzanBeneficial ownership | — | 6.2%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Nima FarzanBeneficial ownership | — | 4.4%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| Timothy LugoBeneficial shares | 166,354 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Timothy LugoBeneficial shares | 166,354 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Neil Singla, M.D.Beneficial shares | 532,795 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Neil Singla, M.D.Beneficial shares | 532,795 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Timothy P. WalbertBeneficial shares | 329,819 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Timothy P. WalbertBeneficial shares | 329,819 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Sara BonsteinBeneficial shares | 105,542 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Sara BonsteinBeneficial shares | 105,542 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Beth Seidenberg, M.D.Beneficial shares | 13,199,669 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| Beth Seidenberg, M.D.Beneficial shares | 13,199,669 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| James B. Tananbaum, M.D.Beneficial shares | 9,041,328 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| James B. Tananbaum, M.D.Beneficial shares | 9,041,328 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| Neil Singla, M.D.Beneficial ownership | — | 1.2%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Beth Seidenberg, M.D.Beneficial ownership | — | 29.9%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| Beth Seidenberg, M.D.Beneficial ownership | — | 20.9%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| James B. Tananbaum, M.D.Beneficial ownership | — | 20.5%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| James B. Tananbaum, M.D.Beneficial ownership | — | 14.3%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| All directors and executive officers as a group (11 persons)Beneficial ownership | — | 54.8%Beneficial | — | SharesBeneficially OwnedPrior to Offering; Percentage |
| All directors and executive officers as a group (11 persons)Beneficial ownership | — | 39.2%Beneficial | — | SharesBeneficially OwnedAfter Offering; Percentage |
| All directors and executive officers as a group (11 persons)Beneficial shares | 26,383,468 | — | — | SharesBeneficially OwnedPrior to Offering; Number |
| All directors and executive officers as a group (11 persons)Beneficial shares | 26,383,468 | — | — | SharesBeneficially OwnedAfter Offering; Number |
| our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliatesOwnership as disclosed | — | approximately 55.8%Beneficial | — | Upon closing of this offering; complete collective group includes executive officers,directors,pre-offering>5%stockholders and their respective affiliates. March31,2026share basis after PreferredStockConversion and ConvertibleNotesConversion; no group offering purchases,no underwriter option exercise,and no outstanding-option exercise. Original paragraph continues across printed page89; not individual or additive ownership. |
| common stockper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Source statement; >; source predicate: owned; primary source clause; full source conditions retained; source scope: of our outstanding common stock before this offering and their respective affiliates will,; not an additive ownership partition
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will,
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Consists of (i) 346,407 shares of Series A-2 Preferred purchased by Westlake BioPartners Fund I, L.P.; (ii) 1,385,629 shares of Series A-2 Preferred purchased by Westlake BioPartners Opportunity Fund I, L.P.; and (iii) 3,464,072 shares of Series A-2 Preferred purchased by Westlake BioPartners Fund II, L.P. Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding stock. Dr. Seidenberg, a member of our board of directors, is a managing director of Westlake BioPartners.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Consists of (i) 1,558,832 shares of Series A-2 Preferred purchased by Foresite Capital Fund V, L.P.; (ii) 1,558,832 shares of Series A-2 Preferred purchased by Foresite Capital Opportunity Fund V, L.P.; and (iii) 779,416 shares of Series A-2 Preferred purchased by Foresite Capital Fund VI LP. Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Consists of (i) 866,018 shares of Series A-2 Preferred purchased by 5AM Opportunities II, L.P.; and (ii) 866,018 shares of Series A-2 Preferred purchased by 5AM Ventures VI, L.P. Entities affiliated with 5AM Ventures hold more than 5% of our outstanding capital stock. Dr. Palestrant, a former member of our board of directors, is a partner at 5AM Ventures. Dr. Palestrant resigned from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
In February 2024, we issued and sold to entities affiliated with Westlake BioPartners an aggregate of 154,137 shares of our common stock at a purchase price of $2.19 per share for aggregate cash proceeds of approximately $0.3 million. 79,326 shares of our common stock were purchased by Westlake BioPartners Fund I, L.P., 27,956 shares of our common stock were purchased by Westlake BioPartners Opportunity Fund I, L.P. and 46,855 shares of our common stock were purchased by Westlake BioPartners Fund II, L.P. Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding capital stock. Dr. Seidenberg, a member of our board of directors, is a managing director at Westlake BioPartners.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Consists of (i) 2,865,054 shares of Series B Preferred purchased by Blue Owl Healthcare Opportunities IV LP; and (ii) 103,749 shares of Series B Preferred purchased by Blue Owl Healthcare Opportunities EF IV LP. Entities affiliated with Blue Owl Healthcare hold more than 5% of our outstanding stock. Mr. Raidy, a member of our board of directors, is a senior managing director of Blue Owl Healthcare.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Entities affiliated with Westlake BioPartners hold more than 5% of our outstanding stock. Dr. Seidenberg, a member of our board of directors, is a managing director at Westlake BioPartners.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding capital stock; not an additive ownership partition
Entities affiliated with 5AM Ventures hold more than 5% of our outstanding capital stock. Dr. Palestrant, a former member of our board of directors, is a partner at 5AM Ventures. Dr. Palestrant resigned from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Consists of (i) 445,320 shares of Series B Preferred purchased by Foresite Capital Fund V, L.P.; (ii) 296,880 shares of Series B Preferred purchased by Foresite Capital Opportunity Fund V, L.P.; and (iii) 742,201 shares of Series B Preferred purchased by Foresite Capital Fund VI LP. Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Entities affiliated with Foresite Capital hold more than 5% of our outstanding stock. Dr. Tananbaum, a member of our board of directors, is the founder and chief executive officer of Foresite Capital.
Source statement; >; source predicate: hold; primary source clause; full source conditions retained; source scope: of our outstanding stock; not an additive ownership partition
Entities affiliated with Blue Owl Healthcare hold more than 5% of our outstanding stock. Mr. Raidy, a member of our board of directors, is a senior managing director of Blue Owl Healthcare.
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Westlake BioPartners(1)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Westlake BioPartners(1)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Foresite Capital(2)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Foresite Capital(2)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with 5AM Ventures(3)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with 5AM Ventures(3)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Entities affiliated with Blue Owl Healthcare(4)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Entities affiliated with Blue Owl Healthcare(4)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Nima Farzan(6)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Nima Farzan(6)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Westlake BioPartners(1)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Westlake BioPartners(1)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Foresite Capital(2)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Foresite Capital(2)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with 5AM Ventures(3)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with 5AM Ventures(3)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Entities affiliated with Blue Owl Healthcare(4)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Entities affiliated with Blue Owl Healthcare(4)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Deep Track Biotechnology Master Fund, Ltd.(5)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Nima Farzan(6)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Nima Farzan(6)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Timothy Lugo(7)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Timothy Lugo(7)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Neil Singla, M.D.(8)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Neil Singla, M.D.(8)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Timothy P. Walbert(9)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Timothy P. Walbert(9)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Sara Bonstein(10)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Sara Bonstein(10)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: Beth Seidenberg, M.D.(12)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: Beth Seidenberg, M.D.(12)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: James B. Tananbaum, M.D.(13)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: James B. Tananbaum, M.D.(13)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Neil Singla, M.D.(8)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: Beth Seidenberg, M.D.(12)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: Beth Seidenberg, M.D.(12)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: James B. Tananbaum, M.D.(13)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: James B. Tananbaum, M.D.(13)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Percentage; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Percentage; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: SharesBeneficially OwnedPrior to Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedPrior to Offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)
Exact source ownership column: SharesBeneficially OwnedAfter Offering; Number; holders may overlap; not an additive partition
Raw source column: SharesBeneficially OwnedAfter Offering; Number; source holder: All directors and executive officers as a group (11 persons)(14)
Upon closing of this offering; complete collective group includes executive officers,directors,pre-offering>5%stockholders and their respective affiliates. March31,2026share basis after PreferredStockConversion and ConvertibleNotesConversion; no group offering purchases,no underwriter option exercise,and no outstanding-option exercise. Original paragraph continues across printed page89; not individual or additive ownership.
Upon the closing of this offering, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock before this offering and their respective affiliates will, 89 Table of Contents in the aggregate, hold approximately 55.8% of our outstanding common stock (based on the number of shares of our common stock outstanding as of March 31, 2026, after giving effect to the Preferred Stock Conversion and Convertible Notes Conversion, and assuming no purchase of shares in this offering by any of this group, no exercise of the underwriters’ option to purchase additional shares of our common stock and no exercise of outstanding options). As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination that other stockholders may desire. The interests of these stockholders may not always coincide with your interests or the interests of other stockholders, and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock. Any of these actions could adversely affect the market price of our common stock.
Literal source per-share voting entitlement; common stock; non-cumulative voting; subject to the express source qualifications; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of stockholders, except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. There are no cumulative voting rights. Source context: Upon the filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 999,999,999 shares of our common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. All of our authorized preferred stock upon the closing of this offering will be undesignated. The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and upon the closing of this offering, respectively, and of the Delaware General Corporation Law (DGCL). This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the DGCL.
Saved control snapshot
The dated saved report retains its own figures and assumptions. These strings are not new calculation inputs.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Existing holdersMajor ownership group | — | ~69.6%* | — | |
| Other disclosed classesMajor ownership group | — | See filing | — | |
| IPO sharesPublic / new investors | — | 19.200M | — |
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
IPO shares are immediately tradable; later supply depends on the final lock-up, option and resale-registration terms.
- Initial float
- 19.200M
- Restricted / potential supply
- 63.24M
- Multiple
- See filing
- Increase
- See filing
Share supply
Source lock-up conditions
Literal day restriction; after date of this prospectus; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stockAfter date of this prospectus · Source conditions apply | 180 days |
| We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or exchangeable for our common stockAfter date of this prospectus · Source conditions apply | 180 days |
Source and calculation
Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares of our common stock, could reduce the market price of our common stock. After this offering, we will have 63,238,030 shares of our common stock outstanding (assuming no exercise of the underwriters’ option to purchase additional shares of our common stock). This includes the shares that we are selling in this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Substantially all of the remaining shares of our common stock initially will be restricted as a result of securities laws, market standoff provisions or lock-up agreements, but will become eligible to be sold after this offering as described in the section titled “Shares Eligible for Future Sale.” We, our directors, our officers and substantially all of the holders of our common stock or securities convertible into, exercisable for, or exchangeable for our common stock have entered into market standoff agreements with us and have entered or will enter into lock-up agreements under which we have agreed or will agree, subject to specific exceptions described in the section titled “Underwriting,” not to offer, sell, or transfer such securities for 180 days following the date of this prospectus. We refer to such period as the lock-up period. Goldman Sachs & Co. LLC, Jefferies LLC and Leerink Partners LLC may, in their sole discretion and at any time or from time to time before the termination of the lock-up period release all or any portion of the securities subject to lock-up agreements.
SEC lock-up paragraph; source 660771:662871; SHA256 08a47f880d064ed30e29d22eaccf1cda5c2dfb974f9d97927b7373edea8d43f5 ↗We and our officers, directors, and holders of substantially all of our common stock and securities convertible into or exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock or securities convertible into or exchangeable for shares of common stock, or collectively, the “Lock-Up Securities,” during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of Goldman Sachs & Co. LLC, Jefferies LLC and Leerink Partners LLC. This agreement does not apply to any existing employee benefit plans. See the section titled “Shares Available for Future Sale” for a discussion of certain transfer restrictions.
SEC lock-up paragraph; source 1765009:1765963; SHA256 9c9d674e753605a6aec7a63997e9a4a7af516081a1142ec6ae5549c099eb7054 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| Over-allotment window | Post-listing See filing · Additional shares only if exercised | Over-allotment window · Additional shares only if exercised |
| Insider resale eligibility | Holder-specific See 424B · Existing-holder supply | Insider resale eligibility · Existing-holder supply |
Basis and evidence
Over-allotment window · Additional shares only if exercised
Lock-up / shares eligible for future sale ↗Insider resale eligibility · Existing-holder supply
Lock-up / shares eligible for future sale ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Operating cash flow
$ · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | ($50,955,000) | ($97,557,000) |
| Calculation | Reported value |
|---|---|
| Cash and cash equivalents2024-12-31 | $17,918,000 |
| Cash and cash equivalents2025-12-31 | $69,437,000 |
| Current assets2024-12-31 | $21,164,000 |
| Current assets2025-12-31 | $73,829,000 |
| Total assets2024-12-31 | $22,864,000 |
| Total assets2025-12-31 | $75,516,000 |
| Current liabilities2024-12-31 | $14,435,000 |
| Current liabilities2025-12-31 | $18,446,000 |
| Total liabilities2024-12-31 | $14,934,000 |
| Total liabilities2025-12-31 | $18,608,000 |
| Total equity / (deficit)2024-12-31 | ($129,599,000) |
| Total equity / (deficit)2025-12-31 | ($231,674,000) |
| General and administrative expensesFY2024 | $6,667,000 |
| General and administrative expensesFY2025 | $10,862,000 |
| Cash and cash equivalents2025-12-31 · Unaudited | $69,437,000 |
| Cash and cash equivalents2026-03-31 · Unaudited | $42,177,000 |
| Current assets2025-12-31 · Unaudited | $73,829,000 |
| Current assets2026-03-31 · Unaudited | $46,843,000 |
| Total assets2025-12-31 · Unaudited | $75,516,000 |
| Total assets2026-03-31 · Unaudited | $50,581,000 |
| Current liabilities2025-12-31 · Unaudited | $18,446,000 |
| Current liabilities2026-03-31 · Unaudited | $14,491,000 |
| Total liabilities2025-12-31 · Unaudited | $18,608,000 |
| Total liabilities2026-03-31 · Unaudited | $14,578,000 |
| Total equity / (deficit)2025-12-31 · Unaudited | ($231,674,000) |
| Total equity / (deficit)2026-03-31 · Unaudited | ($252,579,000) |
| General and administrative expenses3M ended 2025-03-31 · Unaudited | $2,824,000 |
| General and administrative expenses3M ended 2026-03-31 · Unaudited | $5,803,000 |
| Operating cash flow3M ended 2025-03-31 · Unaudited | ($21,157,000) |
| Operating cash flow3M ended 2026-03-31 · Unaudited | ($27,069,000) |
Basis and evidence
Saved snapshot — period not verified
These saved figures have no verified reporting period or currency basis. They are excluded from statement comparisons and calculations.
Financial quality
| Calculation | Reported value |
|---|---|
| Revenue | Pre-revenue |
| Net resultLatest reported | $(111.18M) |
| Market-value referencePost-listing snapshot | $1.41B |
| Shares outstandingLatest reported | 63.24M |
| Offer size19.200M | $345.60M |
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Financial review | Reported financial figures are shown above. A cash-runway estimate needs compatible cash-flow and funding assumptions. Open filing ↗ |
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
Why it mattersChanges dilution, public float and potential supply.
Evidence · 424B4 · 2026/08/07Why it mattersChanges valuation, proceeds and first-day return assumptions.
Evidence · 424B4 · 2026/08/07424B4
• Final prospectus source verified
• Trading began on 2026-08-07 at $18.00
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
The latest reported period remains loss-making.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
The primary-secondary mix, controlling holders and voting rights require the final beneficial-ownership table.
- Potential impact
- High
- Evidence
- 424B4 · 2026/08/07 ↗
Option exercise, employee equity and lock-up expiry can expand tradable supply.
- Potential impact
- Medium
- Evidence
- 424B4 · 2026/08/07 ↗
Sources and calculation notes
Final prospectus, offer price, listing date and headline financial evidence reconciled
View the filing's actual first page +
